Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 30Breast Neoplasms 26Neoplasms 24Neoplasm Metastasis 24Triple Negative Breast Neoplasms 21Parkinson Disease 4, Autosomal Dominant Lewy Body 10Lung Neoplasms 9Melanoma 8Stomach Neoplasms 7Carcinoma, Pancreatic Ductal 7Adenocarcinoma 7Ovarian Neoplasms 6Colorectal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Esophageal Neoplasms 4Digestive System Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Rectal Neoplasms 3Pancreatic Diseases 3Neoplasms by Site 3Lymphoma, Non-Hodgkin 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Endocrine Gland Neoplasms 3Digestive System Diseases 3

Interventions

Gemcitabine 1Albumin-Bound Paclitaxel 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cholestasis × Albumin-Bound Paclitaxel × Clear all
NCT02267707 2019-11-01

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Celgene

Phase 1 Terminated
1 enrolled
Gastrointestinal

Cholestasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡